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Abstract 
Background: Tissue hypoxia induces the degradation of adenosine triphosphate, result-
ing in the production of uric acid (UA). Patients with chronic obstructive pulmonary 
disease (COPD) have been reported to have high serum levels of UA (sUA), compared 
with control subjects. However, the relationship between sUA levels and spirometric 
measures has not been investigated in detail in a general population. 
Methods: Subjects aged 40 years or older (n = 2,917), who had participated in a commu-
nity-based annual health check in Takahata, Japan, in 2004 and 2005, were enrolled in the 
study. These subjects performed spirometry, their blood pressure was measured, and a 
blood sample was taken.  
Results: sUA levels were significantly higher in males than in females. Percent predicted 
forced vital capacity [FVC %predicted] (r = -0.13) and forced expiratory volume in 1 s 
[FEV1 %predicted] (r = -0.118) were inversely correlated with sUA levels in females but 
not in males. Univariate regression analysis indicated that age, body mass index (BMI), 
ethanol intake, mean blood pressure (BP), and serum creatinine (sCr) were significantly 
associated with sUA levels in males. In females, age, BMI, mean BP, hemoglobin A1c, 
sCr, FVC %predicted, and FEV1 %predicted were significantly associated with sUA lev-
els. Multiple linear regression analysis showed that for both genders, FVC %predicted 
and FEV1 %predicted were predictive for sUA levels, independently of the other clinical 
parameters. Subjects with lung restriction had higher sUA levels than subjects without 
lung restriction. In addition, subjects with moderate and severe airflow limitation had 
higher sUA levels than subjects without airflow limitation or those with mild airflow 
limitation. 
Conclusion: FVC %predicted and FEV1 %predicted were significantly associated with 
sUA levels in a general population. 
Key words: uric acid, spirometry, pulmonary function, epidemiology 
INTRODUCTION 
Long-term cigarette smoking injures the respir-
atory system and causes pulmonary diseases such as 
chronic obstructive pulmonary disease (COPD). Even 
in  healthy  individuals,  cigarette  smoking  induces 
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oxidative stress and lung inflammation. As a result of 
damage to lung tissues induced by oxidants and in-
flammation,  pulmonary  function  declines  with 
long-term  exposure  to  smoke  (1,2).  Impairment  of 
pulmonary function reduces oxygen intake, resulting 
in tissue hypoxia. 
Tissue hypoxia has been reported to induce the 
degradation of adenosine (3,4). This results in the re-
lease  of  purine  intermediates  and  end  products  of 
purine catabolism, such as uric acid (UA) (5). Eleva-
tion of serum UA (sUA) levels has been observed in 
hypoxic subjects, including patients with COPD (6-8). 
However,  sUA  levels  are  also  influenced  by  other 
clinical  factors  such  as  gender,  body  mass  index 
(BMI),  daily  intake  of  alcohol,  blood  pressure  (BP), 
and renal function, as indicated by serum creatinine 
(sCr) concentration (9-11).  
Garcia-Larsen  et  al.  performed  a  popula-
tion-based investigation to examine the relationship 
between oxidative stress-related biomarkers, oxidant 
status and asthma and atopy in young adults aged 
22-29 years. That study demonstrated that there was 
no relationship between plasma UA and lung func-
tion (12). However, these relationships were only in-
vestigated in a population of young adults, and the 
association between sUA levels and pulmonary func-
tion  in  the  general  population  remains  to  be  eluci-
dated. 
In this study, we examined the relationship be-
tween spirometric measures and sUA levels in a gen-
eral  population  participating  in  an  annual  health 
check in Takahata, Japan. 
METHODS 
Study population 
This study formed part of the Molecular Epide-
miological  Study,  utilizing  data  from  the  Regional 
Characteristics of 21st Century Centers of Excellence 
(COE) Program and the Global COE Program in Ja-
pan. Details of the study methodology have been de-
scribed elsewhere (2,13). The study was approved by 
the institutional ethics committee and all participants 
gave written informed consent. 
This  study  utilized  data  from  a  communi-
ty-based annual health check, in which all inhabitants 
of Takahata town (population 26,026) in northern Ja-
pan, who were aged 40 years or older, were invited to 
participate. This region has a resident population of 
15,222 adults aged 40 years or older (7,109 males and 
8,113  females).  Since  employees  in  public  institutes 
and many companies are examined annually in the 
health check program organized by local health cen-
ters,  they  usually  do  not  participate  in  the  health 
checks  organized  by  local  government  authorities 
such as Takahata town. The health checks organized 
by  local  government  cover  farmers,  employees  in 
smaller  companies,  self-employed  persons,  house-
wives, and retired persons. Four thousand two hun-
dred  and  eighty-two  adults  aged  40  years  or  older 
participated in this health check program from June 
2004 through November 2005, and 1,380 males and 
1,735 females (a total of 3,165 subjects) agreed to be 
enrolled in the study. Two hundred and forty-eight 
subjects were excluded from the analysis because of 
unsatisfactory spirometry data that did not meet the 
Japanese Respiratory Society (JRS) criteria (14). Data 
for a total of 2,917 subjects (1,325 males, 1,592 females) 
was entered into the final statistical analysis (2). This 
study is a secondary analysis of previously published 
epidemiological  data  demonstrating  an  increased 
prevalence  of  airflow  limitation  among  cigarette 
smokers from the same population (2). 
Subjects  used  a  self-report  questionnaire  to 
document  their  medical  histories,  smoking  habits, 
current medications and clinical symptoms, with 2.2% 
of subjects reporting a history of respiratory disease. 
However, details of the respiratory diseases were not 
specified, because the question on history of respira-
tory disease only required a yes/no answer. 
Measurements 
Systolic and diastolic blood pressures (BPs) were 
measured using a mercury manometer placed on the 
right arm of subjects who had been resting in the sit-
ting position for at least 5 min before the measure-
ment.  Measurements  were  performed  twice,  and 
mean BP was calculated as diastolic BP plus 0.33 x 
(systolic  BP  minus  diastolic  BP)  (15).  Fasting  blood 
samples were taken from the antecubital vein and the 
blood was immediately transferred to chilled tubes.  
Spirometric  parameters  [forced  vital  capacity 
(FVC)  and  forced  expiratory  volume  in  1  s  (FEV1)] 
were measured using standard techniques, with sub-
jects performing FVC maneuvers on a CHESTAC-25 
part  II  EX  instrument  (Chest  Corp.,  Tokyo,  Japan), 
according to the JRS guidelines (14). A bronchodilator 
was not administered prior to spirometry. The highest 
value  from  at  least  three  FVC  maneuvers  by  each 
subject was used in the analysis. Spirometry results 
were  assessed  by  visual  inspection  of  flow-volume 
curves  by  two  pulmonary  physicians,  and  data  for 
subjects with unsatisfactory results, according to the 
JRS criteria, were excluded (14). The predictive equa-
tions  described  by  Osaka  et  al.  (2)  were  used,  and 
percent predicted values for spirometric parameters 
are  presented  as  FVC  %predicted  and  FEV1  %pre-
dicted. Subjects with FEV1/FVC <70% were identified Int. J. Med. Sci. 2011, 8 
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as  having  airflow  limitation,  and  those  with  FVC 
%predicted <80% were identified as having lung re-
striction.  According  to  the  Global  initiative  for 
Chronic  Obstructive  Lung  Disease  (GOLD)  criteria, 
subjects with airflow limitation and FEV1 %predicted 
≥80 were identified as having mild air flow limitation, 
those with 50≤ FEV1 %predicted <80 were defined as 
having moderate air flow limitation, and those with 
FEV1 %predicted <50 were defined as having severe 
airflow limitation (1). In addition, subjects with lung 
restriction were divided into two groups: those with 
70≤ FVC %predicted <80 and those with FVC %pre-
dicted <70. Those with FVC %predicted <70 consti-
tuted the lowest 2.5% percentile of all subjects in the 
study population. 
Measurements  of  PaO2  by  arterial  blood  gas 
analysis  or  of  oxygen  saturation  by  pulse  oximetry 
were  not  performed  in  this  health  check  program. 
Because this study was performed using data from the 
health  check  program,  information  on  chest  X-ray 
findings and the final diagnosis for each subject were 
not available. 
Statistical analysis 
Differences between two groups were analyzed 
using  Student’s  t-test  or  the  Mann-Whitney  U  test. 
Multiple  comparisons  were  performed  using 
non-parametric one way analysis of variance (Krus-
kal-Wallis  test)  followed  by  the  Stu-
dent-Newman-Keuls test. These analyses, as well as 
regression analyses and logistic regression analyses, 
were performed using SigmaPlot version 11 computer 
software  (Systat  Software,  Inc.,  San  Jose,  CA,  USA) 
and JMP version 8 software (SAS Institute Inc., Cary, 
NC, USA). Data in the figures are means ± SD. Sig-
nificance was inferred for differences with  P values 
<0.05. 
RESULTS 
The  characteristics  of  the  subjects  are  summa-
rized according to gender in Table 1. Age, smoking 
index, daily intake of ethanol, mean BP, sCr and sUA 
levels were significantly higher in male than in female 
subjects.  In  contrast,  BMI  and  hemoglobin  A1c 
(HbA1c)  concentration  did  not  differ  significantly 
between  males  and  females.  FVC  %predicted  and 
FEV1  %predicted  were  significantly  lower  in  males 
than in females. FVC %predicted was weakly but sig-
nificantly  associated  with  BMI  (r  =0.07,  P  =0.008), 
smoking  index  (r  =-0.14,  P  <0.0001),  ethanol  con-
sumption  (r  =0.06,  P  =0.044),  mean  BP  (r  =0.06,  P 
=0.019), and HbA1c (r =-0.09, P =0.001) in male sub-
jects.  In  females,  FVC  %predicted  was  weakly  but 
significantly  associated  with  mean  BP  (r  =-0.07,  P 
=0.006), HbA1c (r =-0.06, P =0.012) and sCr (r =-0.05, P 
=0.029).  FEV1  %predicted  was  weakly  but  signifi-
cantly associated with age (r =-0.11, P <0.0001), BMI (r 
=0.13, P <0.0001), smoking index (r =-0.20, P <0.0001), 
and mean BP (r =0.06, P =0.043) in male subjects. In 
females,  FEV1  %predicted  was  weakly  but  signifi-
cantly  associated  with  smoking  index  (r  =-0.05,  P 
=0.034) and mean BP (r =-0.05, P =0.044). 
 
Table 1. Differences in the characteristics of male and 
female subjects 
All subjects (n=2917)  Males (n=1325)  Females (n=1592) 
Age, years  63.2 ± 10.3  62.5 ± 10.1* 
BMI, kg/m2  23.5 ± 3.0  23.6 ± 3.4 
Smoking index  279.4 ± 406.0  13.6 ± 77.5** 
Ethanol intake, g/day  23.2 ± 22.5  2.5 ± 8.0** 
Mean BP, mm Hg  99.8 ± 11.0  95.6 ± 10.9** 
HbA1C, %  5.2 ± 0.8  5.2 ± 0.6 
sCr, mg/dL  0.78 ± 0.27  0.59 ± 0.11** 
Uric acid, mg/dL  5.8 ± 1.3  4.5 ± 1.1** 
FVC %predicted  97.6 ± 14.7  100.2 ± 14.4** 
FEV1 %predicted  95.7 ± 17.5  99.9 ± 15.6** 
Differences in smoking index and ethanol intake between males 
and females were assessed for statistical significance using the 
Mann-Whitney U test. 
Data are mean ± SD. *P <0.05 compared with male subjects, **P 
<0.001 compared with male subjects. 
Smoking index = daily consumption of cigarettes x years of smok-
ing 
Ethanol intake = grams of ethanol consumed per day 
Mean BP = diastolic BP + (average systolic BP - average diastolic 
BP)/3 
BMI, body mass index; BP, blood pressure; HbA1c, hemoglobin 
A1c; sCr, serum creatinine; FVC %predicted, percent predicted 
forced vital capacity; FEV1 %predicted, percent predicted forced 
expiratory volume in 1 s 
 
 
Figure  1  shows  the  relationships  between  spi-
rometric parameters and sUA levels. In males, FVC 
%predicted  and  FEV1  %predicted  were  not  signifi-
cantly associated with sUA (Fig. 1A & 1C). However, 
in females, there were inverse relationships between 
these spirometric parameters and sUA levels (Fig. 1B 
& 1D). 
Univariate  regression  analysis  demonstrated 
that in male subjects, age, BMI, daily ethanol intake, 
mean BP, and sCr were significantly associated with 
sUA levels (Table 2A). In females, age, BMI, mean BP, 
HbA1c, sCr, FVC %predicted and FEV1 %predicted 
were significantly associated with sUA levels (Table 
2A).  Multiple  linear  regression  analysis  was  per-
formed to assess whether these spirometric parame-
ters were independently associated with sUA levels. Int. J. Med. Sci. 2011, 8 
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Because FVC %predicted and FEV1 %predicted were 
strongly  correlated  (r  =  0.847,  P  <0.0001),  these  pa-
rameters  were  assessed  separately  to  avoid  con-
founding (Table 2B & 2C). As shown in Table 2, FVC 
%predicted and FEV1 %predicted were predictive for 
sUA levels, independently of age, BMI, smoking in-
dex, daily ethanol intake, mean BP, HbA1c and sCr, 
both in males and females. We also examined if pul-
monary dysfunction was an independent risk factor 
for hyperuricemia (sUA >7 mg/dL), independently of 
age, BMI, smoking index, daily ethanol intake, mean 
BP, HbA1c and sCr, using multiple logistic analysis. 
As shown in Table 3, FVC %predicted was predictive 
for hyperuricemia, independently of these factors in 
female  (P  =0.002),  not  in  males  (P  =0.075).  FEV1 
%predicted  was  predictive  for  hyperuricemia,  inde-
pendently of these factors in both genders (male:  P 
=0.002, females: P <0.001). 
Elevation of sUA levels according to the degree 
of impairment of pulmonary function was also inves-
tigated. Subjects were categorized according to their 
FVC %predicted and FEV1 %predicted values (Fig. 2). 
To avoid using data for the subjects with airflow lim-
itation and lung restriction from the referent group, 
those subjects were excluded from the analyses. Sub-
jects with lung restriction [FVC %predicted <70, and 
70≤ FVC %predicted <80] had higher sUA levels than 
subjects without lung restriction [FVC %predicted ≥
80] (Fig. 2A). Subjects with moderate or severe airflow 
limitation had higher sUA levels than subjects with-
out airflow limitation or those with mild airflow lim-
itation (Fig. 2B). 
 
Table 2. Univariate and multivariate regression analyses to identify factors that were predictive for serum uric acid 
levels 
  Males    Females 
  Coefficient  SE  P value    Coefficient  SE  P value 
A. Univariate regression analysis               
Age, years  -0.019   0.003   <.0001    0.014   0.003   <.0001 
BMI, kg/m2  0.090   0.012   <.0001    0.079   0.008   <.0001 
Smoking index  0.000   0.000   0.082     0.000   0.000   0.779  
Ethanol intake, g/day  0.006   0.002   <.0001    0.000   0.003   0.974  
Mean BP, mmHg  0.013   0.003   <.0001    0.016   0.002   <.0001 
HbA1c, %  -0.053   0.047   0.261     0.243   0.045   <.0001 
sCr, mg/dL  1.237   0.125   <.0001    3.080   0.225   <.0001 
FVC %predicted  -0.004   0.002   0.064     -0.010   0.002   <.0001 
FEV1 %predicted  -0.002   0.002   0.305       -0.008   0.002   <.0001 
B. Multivariate regression analysis, model 1               
Age, years  -0.016   0.003   <.0001    0.006   0.003   0.019  
BMI, kg/m2  0.076   0.012   <.0001    0.061   0.008   <.0001 
Smoking index  0.000   0.000   0.111     0.000   0.000   0.640  
Ethanol intake, g/day  0.005   0.002   0.000     0.007   0.003   0.027  
Mean BP, mmHg  0.007   0.003   0.018     0.008   0.002   0.001  
HbA1c, %  -0.077   0.045   0.086     0.142   0.042   0.001  
sCr, mg/dL  1.297   0.121   <.0001    2.947   0.217   <.0001 
FVC %predicted  -0.006   0.002   0.009       -0.007   0.002   <.0001 
C. Multivariate regression analysis, model 2               
Age, years  -0.016   0.003   <.0001    0.006   0.003   0.021  
BMI, kg/m2  0.076   0.012   <.0001    0.062   0.008   <.0001 
Smoking index  0.000   0.000   0.136     0.000   0.000   0.674  
Ethanol intake, g/day  0.005   0.002   0.001     0.007   0.003   0.035  
Mean BP, mmHg  0.007   0.003   0.020     0.008   0.002   0.001  
HbA1c, %  -0.070   0.045   0.119     0.143   0.042   0.001  
sCr, mg/dL  1.297   0.121   <.0001    2.963   0.216   <.0001 
FEV1 %predicted  -0.004   0.002   0.030       -0.007   0.002   <.0001 
BMI, body mass index; BP, blood pressure; HbA1c, hemoglobin A1c; sCr, serum creatinine; FVC %predicted, percent predicted forced vital 
capacity; FEV1 %predicted, percent predicted forced expiratory volume in 1 s 
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Table 3. Multiple logistic analyses to identify factors that were predictive for hyperuricemia (serum uric acid >7.0 
mg/dL) 
  Males    Females 
  OR  95% CI  P    OR  95% CI  P 
A. Model 1                   
Age (per 1 year increase)  0.975   (0.962,   0.988)   0.000     1.039   (1.008,   1.072)   0.014  
BMI (per 1 kg/m2 increase)  1.117   (1.066,   1.172)   <.0001    1.128   (1.042,   1.223)   0.003  
Smoking index  (per 1 cig/y increase)  1.000   (1.000,   1.000)   0.750     -      -  
Ethanol intake (per 1 g/day increase)  1.011   (1.005,   1.017)   0.000     1.014   (0.966,   1.046)   0.494  
mean BP  (per 1 mmHg increase)  1.018   (1.006,   1.031)   0.004     1.012   (0.985,   1.039)   0.384  
HbA1C  (per 1 % increase)  0.930   (0.760,   1.123)   0.461     1.306   (0.863,   1.838)   0.198  
sCr  (per 0.1 mg/dL increase)  6.139   (2.324,   16.851)   <.0001    20.703   (3.167,   165.303)   <.0001 
FVC % predicted (per 1% increase)  0.991   (0.982,   1.001)   0.075      0.970   (0.952,   0.989)   0.002  
B. Model 2                   
Age (per 1 year increase)  0.973   (0.960,   0.987)   <.0001    1.039   (1.007,   1.073)  0.016  
BMI (per 1 kg/m2 increase)  1.120   (1.068,   1.175)   <.0001    1.131   (1.045,   1.226)   0.002  
Smoking index  (per 1 cig*y increase)  1.000   (1.000,   1.000)   0.881     -      - 
Ethanol intake (per 1 g/day increase)  1.011   (1.005,   1.017)   0.000     1.013   (0.966,   1.045)   0.518  
mean BP  (per 1 mmHg increase)  1.019   (1.006,   1.032)   0.004     1.014   (0.987,   1.041)   0.316  
HbA1C  (per 1 % increase)  0.937   (0.766,   1.130)   0.506     1.329   (0.880,   1.864)   0.169  
sCr  (per 0.1 mg/dL increase)  6.374   (2.411,   17.515)   <.0001    23.081   (3.464,   185.534)   <.0001 
FEV1 % predicted (per 1% increase)  0.991   (0.983,   1.000)   0.038     0.970   (0.954,   0.986)   <.001  
In females, OR and 95% CI for smoking index could not be obtained by the analyses using the computer software. 
BMI, body mass index; BP, blood pressure; HbA1c, hemoglobin A1c; sCr, serum creatinine; FVC %predicted, percent predicted forced vital 
capacity; FEV1 %predicted, percent predicted forced expiratory volume in 1 s; OR, odds ratio; CI, confidence interval 
 
 
Figure 1. Correlations between spirometric parameters and serum uric acid levels in males and females. Graphs show 
the relationships of FVC %predicted (A & B) and FEV1 %predicted (C & D) with serum uric acid in males (A & C) and females 
(B & D). In males, FVC %predicted and FEV1 %predicted were not significantly associated with serum uric acid levels (A & C). 
However, in females, there were inverse relationships between these spirometric parameters and serum uric acid levels (B 
& D). Int. J. Med. Sci. 2011, 8 
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Figure 2. Serum uric acid levels according to degree of 
lung  restriction  and  airflow  limitation.  Subjects  were 
categorized into three groups according to degree of lung 
restriction: FVC %predicted ≥80, 70≤ FVC %predicted <80, 
and  FVC  %predicted  <70.  Subjects  were  categorized  as 
having airflow limitation if FEV1/FVC was <0.7, according 
to the Global Initiative for Obstructive Lung Disease (GOLD) 
criteria. Airflow limitation was classified as mild if FEV1 
%predicted was ≥80, moderate if 50≤ FEV1 %predicted was 
<80 and severe if FEV1 %predicted was <50. To avoid using 
data for subjects with airflow limitation and lung restriction 
from  the  referent  group,  those  subjects  were  excluded 
from the analyses shown in (A) and (B). Subjects with lung 
restriction [FVC %predicted <70, and 70≤ FVC %predicted 
<80] had higher serum uric acid levels than subjects without 
lung  restriction  [FVC  %predicted  ≥80]  (A).  Subjects  with 
moderate or severe airflow limitation had higher serum uric 
acid levels than subjects without airflow limitation or those 
with  mild  airflow  limitation  (B).  Statistical  comparisons 
were  performed  by  ANOVA  followed  by  the  Stu-
dent-Newman-Keuls  test.  *P  <  0.05  compared  with  FVC 
%predicted ≥ 80, ***P < 0.001 compared with no airflow 
limitation, #P < 0.05 compared with mild airflow limitation, 
##P < 0.01 compared with mild airflow limitation. 
DISCUSSION 
This study demonstrated that there were signif-
icant  inverse  correlations  between  spirometric  pa-
rameters  (FVC  %predicted,  r  =-0.130;  FEV1  %pre-
dicted, r =-0.118) and sUA levels in female subjects 
who participated in an annual health check. Although 
these  univariate  correlations  were  not  observed  for 
male subjects, multiple linear regression analysis re-
vealed  that  FVC  %predicted  and  FEV1  %predicted 
were significant predictive factors for sUA levels, in-
dependently of age, BMI, smoking index, daily etha-
nol intake, mean BP, HbA1c and sCr, not only in fe-
males but also in males. Multiple logistic analysis re-
vealed  that  FVC  %predicted  in  females  and  FEV1 
%predicted in both genders were significant predic-
tive for hyperuricemia. Therefore, we concluded that 
there were significant associations between spiromet-
ric measures and sUA levels in the Japanese general 
population. 
UA  is  the  end-product  of  purine  degradation 
(16). Excessive intake of foods containing purine bases 
(17), alcohol consumption (18), renal dysfunction (19), 
and genetic disorders of purine metabolism, such as 
hypoxanthine-guanine  phosphoribosyltransferase 
deficiency (Lesch-Nyhan syndrome) (20) and adenine 
phosphoribosyltransferase  deficiency  (21),  result  in 
elevation  of  sUA  levels.  In  addition,  other  demo-
graphic  and  clinical  factors,  such  as  gender,  BMI, 
smoking  index,  BP  and  serum  glucose  levels,  are 
known  to  be  associated  with  serum  levels  of  UA 
(9-11). Therefore, careful consideration of these factors 
is required when assessing the relationship between 
pulmonary function and UA levels. 
UA is a biomarker of xanthine oxidase activity, 
which is known to be an important source of reactive 
oxygen  species  (22,23).  Several  investigators  have 
reported that elevated UA levels were associated with 
worsening of cardiovascular disease, heart failure and 
COPD (6,24-26). In Japanese patients receiving home 
oxygen  therapy,  mortality  was  reportedly  high 
among those with high sUA levels (27). In addition, 
positive associations were demonstrated between UA 
and inflammatory markers such as C-reactive protein 
and  interleukin-6  (28).  These  findings  suggest  that 
systemic  UA  levels  are  associated  with  oxidative 
stress and inflammation in vivo. UA activates leuko-
cytes through the NALP3  inflammasome  (29). Acti-
vated leukocytes express selectins and adhere to en-
dothelial  cells,  where  they  secrete  various 
pro-inflammatory cytokines and chemical mediators, 
resulting in vessel wall damage and atherosclerosis. 
In contrast to these cytotoxic properties, UA is 
known to be involved in the elimination of reactive Int. J. Med. Sci. 2011, 8 
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oxygen species (ROS) (30,31). Therefore, UA appears 
to function as a double-edged sword  in vivo. While 
UA  is  a  pro-inflammatory  molecule  for  endothelial 
cells,  it  functions  as  a  powerful  antioxidant  in  the 
upper  airways  (32).  Indeed,  patients  with  hypouri-
cemia  due  to  a  genetic  disorder  affecting  uric  acid 
transporter 1 sometimes experience acute renal failure 
after strenuous exercise (33). The mechanism of renal 
dysfunction after exercise is thought to involve a re-
duced capacity for eliminating ROS (34,35). Therefore, 
the roles of UA in vivo are not simple due to this dual 
function. The crystalline form of UA is reported to be 
a strong inducer of inflammation, and hyperuricemia 
contributes to the formation of UA crystals (29). Thus, 
there may be optimal levels of UA to ensure homeo-
stasis of ROS levels in mammalian tissues. 
Possible  explanations  for  the  association  be-
tween sUA levels and pulmonary function, as identi-
fied in the present study are 1) that hypoxia in sub-
jects with impaired pulmonary function induces the 
production of UA, 2) that impaired pulmonary func-
tion induces pulmonary hypertension, resulting in the 
elevation of sUA levels, 3) that oxidative stress and 
inflammation induce lung tissue damage, resulting in 
the elevation of UA levels, or conversely, 4) that ele-
vated  levels  of  UA  cause  systemic  inflammation, 
which eventually results in impairment of pulmonary 
function. 
First, UA levels have been shown to be increased 
in  hypoxic  states.  Elsayed  et  al.  demonstrated  that 
experimentally-induced hypoxia resulted in substan-
tially higher UA concentrations in lung perfusate and 
lung  tissues  of  animals,  as  compared  with  either 
normoxia  or  hyperoxia  (5).  Therefore,  it  has  been 
suggested that pulmonary hypoxia promotes purine 
catabolism,  leading  to  increased  production  of  UA. 
Unfortunately, measurements of PaO2 or oxygen sat-
uration were not performed in the health check pro-
gram, and this  was not a hospital-based clinical re-
search study. Although the lack of this data is a limi-
tation of the present study, multiple linear regression 
analysis revealed that pulmonary function was a sig-
nificant  determinant  of  serum  UA  levels,  inde-
pendently of age, gender, BMI, smoking index, alco-
hol consumption, BP, glucose levels, and renal func-
tion. However, it is still open to question whether low 
grade hypoxia, as observed in a general population, 
can affect serum UA levels, because in this study, the 
percentage  of  subjects  with  severe  impairment  of 
pulmonary function was not high. 
Second, subjects with reduced pulmonary func-
tion may have elevated pulmonary arterial pressure. 
In  patients  with  COPD,  pulmonary  hypertension  is 
sometimes induced by loss of pulmonary vasculature 
and hypoxic vascular contraction. In some fibrosing 
lung diseases, impaired functioning of the pulmonary 
vasculature  frequently  causes  pulmonary  hyperten-
sion  (36).  Voelkel  et  al.  reported  an  association  be-
tween  UA  levels  and  pulmonary  arterial  pressure 
(37).  This  alteration  of  hemodynamics  may  elevate 
sUA  levels.  However,  pulmonary  arterial  pressure 
was not measured in this study population. 
Third, cigarette smoke is an important risk factor 
for  many  lung  diseases,  including  COPD  and  pul-
monary  fibrosis.  As  cigarette  smoke  contains  many 
toxic  and  highly  oxidative  compounds,  oxidative 
stress is increased in the alveolar spaces of the lungs 
of smokers, due to the formation of ROS such as su-
peroxide  anion  and  hydrogen  peroxide  by  alveolar 
macrophages  (38-40).  This  oxidative  stress  induces 
lung inflammation, and eventually causes remodeling 
of the airways as a result of tissue damage. Chronic 
pulmonary  inflammation  and  elevated  oxidative 
stress in the alveolar spaces contribute to the patho-
genesis of chronic respiratory diseases, such as COPD 
and pulmonary fibrosis, and cause chronic damage to 
the  lung  structure.  sUA  levels  may  be  elevated  ac-
cording to the severity of tissue damage, as has been 
observed in tumor lysis syndrome (41). Therefore, in 
subjects with high levels of lung oxidative stress and 
inflammation, circulating UA levels may be elevated 
as a result of lung tissue damage. 
Fourth,  accumulating  evidence  suggests  that 
hyperuricemia is a risk factor for cardiovascular dis-
ease (24,25). Hyperuricemia results in the production 
of UA crystals that precipitate in the joints and kidney 
tissues. Despite its anti-oxidative characteristics, UA 
activates  leukocytes  through  the  NALP3  inflam-
masome  (29).  Subsequently,  activated  leukocytes 
cause  damage  to  vascular  endothelial  cells.  As 
demonstrated by other investigators, as well as our 
studies,  pulmonary  endothelial  dysfunction  is  in-
volved in the pathogenesis of COPD  (42,43). There-
fore, hyperuricemia-induced endothelial dysfunction 
is  possibly  associated  with  impaired  pulmonary 
function in the general population. 
Twenty-eight percent of adults aged 40 years or 
older received health examinations organized by the 
Takahata local government, and 74% of these subjects 
were  enrolled  in  this  study.  However,  workers  in 
public institutes and many companies did not partic-
ipate in this research for the reasons described in the 
Methods. Differences in employment, socio-economic 
status  or  life  style  between  participants  and 
non-participants may result in sampling bias. Unfor-
tunately,  personal  information  regarding  employ-
ment, annual income or details of life style were not 
available  for  these  subjects.  Therefore,  further  anal-Int. J. Med. Sci. 2011, 8 
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yses could not be performed, which was a limitation 
of the present study. 
In conclusion, FVC %predicted and FEV1 %pre-
dicted were significantly associated with sUA levels 
in  a  general  population.  Further  investigations  are 
required  to  clarify  the  mechanisms  underlying  this 
association between serum UA levels and pulmonary 
function. 
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